Targeting pathways and integrated approaches to treat Rheumatoid Arthritis

IF 3 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Shradha Devi Dwivedi, Krishna Yadav, Anita Bhoi, Keshav Kant Sahu, Neelam Sangwan, Deependra Singh, Manju Singh
{"title":"Targeting pathways and integrated approaches to treat Rheumatoid Arthritis","authors":"Shradha Devi Dwivedi, Krishna Yadav, Anita Bhoi, Keshav Kant Sahu, Neelam Sangwan, Deependra Singh, Manju Singh","doi":"10.1615/critrevtherdrugcarriersyst.2023044719","DOIUrl":null,"url":null,"abstract":"Rheumatoid arthritis (RA) is a chronic symmetrical systemic disorder that not only affects joints but also other organs such as heart, lungs, kidney, and liver. Approximately there is 0.5% -1% of the total population affected by rheumatoid arthritis. RA pathogenesis still remains unclear due to which its appropriate treatment is a challenge. Further, multitudes of factors have been reported to affect its progression i.e. genetic factor, environmental factor, immune factor, and oxidative factor. Therapeutic approaches available for the treatment of RA include NSAIDs, DMARDs, enzymatic, hormonal, and gene therapies. But most of them provide the symptomatic relief without treating the core of the disease. This makes it obligatory to explore and reach the molecular targets for cure and long term relief from rheumatoid arthritis. Herein, we attempt to provide extensive overlay of the new targets for RA treatment such as signalling pathways, proteins, and receptors affecting the progression of the disease and its severity. Precise modification in these targets such as suppressing the notch signalling pathway, SIRT 3 protein, Sphingosine-1-phosphate receptor and stimulating the neuronal signals particularly efferent vagus nerve and SIRT 1 protein may offer long term relief and potentially diminish the chronicity. To target or alter the novel molecules and signaling pathway a specific delivery system is required such as liposome, nanoparticles and micelles and many more. In these review paper we have discuss about novel targets and delivery system for treating RA.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Therapeutic Drug Carrier Systems","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2023044719","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Rheumatoid arthritis (RA) is a chronic symmetrical systemic disorder that not only affects joints but also other organs such as heart, lungs, kidney, and liver. Approximately there is 0.5% -1% of the total population affected by rheumatoid arthritis. RA pathogenesis still remains unclear due to which its appropriate treatment is a challenge. Further, multitudes of factors have been reported to affect its progression i.e. genetic factor, environmental factor, immune factor, and oxidative factor. Therapeutic approaches available for the treatment of RA include NSAIDs, DMARDs, enzymatic, hormonal, and gene therapies. But most of them provide the symptomatic relief without treating the core of the disease. This makes it obligatory to explore and reach the molecular targets for cure and long term relief from rheumatoid arthritis. Herein, we attempt to provide extensive overlay of the new targets for RA treatment such as signalling pathways, proteins, and receptors affecting the progression of the disease and its severity. Precise modification in these targets such as suppressing the notch signalling pathway, SIRT 3 protein, Sphingosine-1-phosphate receptor and stimulating the neuronal signals particularly efferent vagus nerve and SIRT 1 protein may offer long term relief and potentially diminish the chronicity. To target or alter the novel molecules and signaling pathway a specific delivery system is required such as liposome, nanoparticles and micelles and many more. In these review paper we have discuss about novel targets and delivery system for treating RA.
治疗类风湿关节炎的靶向途径和综合方法
类风湿性关节炎(RA)是一种慢性对称性全身性疾病,不仅会影响关节,还会影响心脏、肺、肾和肝脏等其他器官。大约有0.5% -1%的人口受到类风湿关节炎的影响。RA的发病机制尚不清楚,因此其适当的治疗是一个挑战。此外,据报道,多种因素影响其进展,如遗传因素、环境因素、免疫因素和氧化因素。可用于治疗类风湿性关节炎的治疗方法包括非甾体抗炎药、dmard、酶、激素和基因治疗。但它们大多只是缓解症状,而没有治疗疾病的核心。这使得探索和达到治疗和长期缓解类风湿性关节炎的分子靶点势在必行。在此,我们试图提供广泛覆盖的RA治疗新靶点,如影响疾病进展及其严重程度的信号通路、蛋白质和受体。对这些靶点进行精确修饰,如抑制notch信号通路、SIRT - 3蛋白、鞘氨醇-1-磷酸受体,刺激神经元信号,特别是传出迷走神经和SIRT -1蛋白,可能会提供长期的缓解,并可能减少慢性。为了靶向或改变新的分子和信号通路,需要一种特定的递送系统,如脂质体、纳米颗粒和胶束等。本文就治疗类风湿性关节炎的新靶点和给药系统进行了综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.50
自引率
18.50%
发文量
27
审稿时长
>12 weeks
期刊介绍: Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields. Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信